ABSTRACT
Introduction Bullous pemphigoid (BP) is the most common autoimmune blistering disease. It predominately afflicts the elderly and is significantly associated with increased mortality. The observation of age-dependent changes in the skin microbiota as well as its involvement in other inflammatory skin disorders suggests that skin microbiota may play a role in the emergence of BP blistering. We hypothesize that changes in microbial diversity associated with BP might occur before the emergence of disease lesions, and thus could represent an early indicator of blistering risk.
Objectives The present study aims to investigate potential relationships between skin microbiota and BP and elaborate on important changes in microbial diversity associated with blistering in BP.
Methods The study consisted of an extensive sampling effort of the skin microbiota in patients with BP and age- and sex-matched controls to analyze whether intra-individual, body site, and/or geographical variation correlate with changes in skin microbial composition in BP and/or blistering status.
Results We find significant differences in the skin microbiota of patients with BP compared to that of controls, and moreover that disease status rather than skin biogeography (body site) governs skin microbiota composition in patients with BP. Our data reveal a discernible transition between normal skin and the skin surrounding BP lesions, which is characterized by a loss of protective microbiota and an increase in sequences matching Staphylococcus aureus, a known inflammation-promoting species. Notably, S. aureus is ubiquitously associated with BP disease status, regardless of the presence of blisters.
Conclusion The present study suggests S. aureus may be a key taxon associated with BP disease status. Importantly, differences in a few key indicator taxa reliably discriminate between patients with BP and matched controls. This may serve as valuable information for assessing blistering risk and treatment outcomes in a clinical setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the German Research Foundation (DFG), through Clinical Research Unit 303, project number 269234613, subproject P2, jointly awarded to Prof. Dr. John F. Baines and Prof. Dr. Dr. Enno Schmidt.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Luebeck ethics committee (15-051, 18-046), as well as the respective committees of the study centers, following the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Manuscript updated; Supplemental files updated
Data Availability
Datasets related to this article can be found under BioProject accession number PRJNA715468 at https://www.ncbi.nlm.nih.gov/bioproject/, an open-source online data repository hosted at the NCBI SRA BioProject database.
https://dataview.ncbi.nlm.nih.gov/object/PRJNA715468?reviewer=tpob0l00b03qg88ju4lqnp7dou
Abbreviations
- AI
- autoimmune
- BP
- bullous pemphigoid
- AIBD
- Autoimmune blistering disease
- (BPDAI)
- Bullous Pemphigoid Disease Area Index
- DF
- degrees of freedom
- IS
- indicator species
- ASV
- amplicon sequence variant
